000 02324cam a2200349 a 4500
003 EG-GiCUC
005 20250223031656.0
008 170228s2016 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.08.08.Ph.D.2016.Sh.P
100 0 _aShahinaze Amry Aly Fouad
245 1 0 _aPharmaceutical study on certain selective serotonin reuptake inhibitor /
_cShahinaze Amry Aly Fouad ; Supervised Saadia Ahmed Tayel , Mohamed Ahmed Elnabarawi , Emad B. Basalious
246 1 5 _aدراسة صيدلية لأحد مثبطات إعادة تحصيل السيروتونين
260 _aCairo :
_bShahinaze Amry Aly Fouad ,
_c2016
300 _a200 P. :
_bcharts ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520 _aDapoxetine, as dapoxetine hydrochloride (D), is the first and only selective serotonin reuptake inhibitor licensed for the treatment of PE in men. However, oral D suffers from extensive first pass metabolism, resulting in poor bioavailability (42%). Therefore, transmucosal systems of D were designed in an attempt to increase its bioavailability. In chapter (I), a 2².3¹ full factorial design was employed to study the effect of different formulation variables. An optimized formulation was prepared and evaluated. It showed a rapid permeation compared to the drug suspension. In chapter (II), nanocarrier systems for transmucosal delivery of D were prepared. In chapter (III), Part (I) and (II) involved determination of the pharmacokinetics of D after sublingual and intranasal delivery from ISTM compared to the oral market product (priligy® 30 mg, tablets) and after the intranasal delivery of D from IDNP of the optimized formulation compared to the oral D-loaded nanocarrier formulation
530 _aIssued also as CD
653 4 _aDapoxetine hydrochloride
653 4 _aLyophilized matrices
653 4 _aSelective serotonin reuptake inhibitor
700 0 _aEmad B. Basalious ,
_eSupervisor
700 0 _aMohamed Ahmed Elnabarawi ,
_eSupervisor
700 0 _aSaadia Ahmed Tayel ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c60031
_d60031